|Dr. Ali Tehrani||Co-Founder, Pres, CEO & Director||902.94k||N/A||1972|
|Dr. Anthony J. Polverino||Chief Scientific Officer & Exec. VP of Early Devel.||578.38k||N/A||1963|
|Ms. Kathryn O'Driscoll||Chief People Officer||108.89k||N/A||1964|
|Dr. Diana F. Hausman||Chief Medical Officer||646.51k||N/A||1963|
|Dr. Neil Josephson M.D.||Sr. VP of Clinical Research||564.13k||N/A||N/A|
|Mr. Neil A. Klompas C.A., CPA, CPA, CA||Exec. VP of Bus. Operations & CFO||N/A||N/A||1972|
|Dr. Surjit Dixit||VP of Technology||N/A||N/A||1973|
|Mr. Daniel Dex||VP of Legal & Corp. Sec.||N/A||N/A||N/A|
|Mr. Mark Hollywood||Sr. VP of Technical & Manufacturing Operations||N/A||N/A||1969|
|Dr. Bruce Hart Ph.D.||Sr. VP of Regulatory||N/A||N/A||N/A|
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; collaboration with Applied BioMath, LLC.; and a research collaboration with ImmunoPrecise Antibodies Ltd. for the development of multiple antibody candidates to fight COVID-19. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Zymeworks Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.